From left: Elisa Port, MD, FACS; Isabel S. Blumberg, MD; Stafford R. Broumand, MD; Hanna Y. Irie, MD, PhD; Laurie Margolies, MD, Director of Breast Imaging, Dubin Breast Center; Jeffrey Mechanick, MD, Professor of Medicine (Cardiology, Endocrinology, Diabetes and Bone Disease); and Hank Schmidt, MD, PhD.
Are breast implants safe? Do oral contraceptives increase your risk for breast cancer? These were among the questions answered by a panel of physicians in May, at the seventh annual Dubin Breast Center Fact vs. Fiction Luncheon and Symposium that was held in Manhattan.
The sold-out event featured the latest information on breast cancer from six doctors at the Icahn School of Medicine at Mount Sinai and was moderated by Elisa Port, MD, FACS, Director of the Dubin Breast Center and Chief of Breast Surgery, Mount Sinai Health System. The goal of the annual luncheon is to clarify information about one of the most common cancers in women worldwide, so patients can keep up with advances and make informed decisions about their health.
“There is no one who gets a diagnosis of breast cancer who doesn’t think it’s the worst day of their life, the worst thing that’s happened to them, and the question of mortality always comes up,” Dr. Port said at the luncheon. “But let me be crystal clear that with a diagnosis of breast cancer there is so much room for optimism in 2019. For most cases, we are saying you have a 90 percent chance of survival. In some cases, a 98 percent or 99 percent chance of survival. This is success.”
Dr. Port said the development of “a few key drugs” over the past decade has led to increased survival rates. “What we need to work on are the outliers that don’t respond well. That continues to be the reason we get up every morning and sit in the lab and look for better treatments,” she added. “You will hear more from us, because we are on it.”
The following questions and answers were among those included at the luncheon.
Do birth control pills increase my risk for breast cancer?
Isabel S. Blumberg, MD, Clinical Instructor, Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine: Yes. Even newer ones slightly increase the risk for breast cancer. The risk is very small. Someone who has had breast cancer is not a candidate for oral contraceptives. But there is a nonhormonal IUD that is really safe, lasts for 10 years, and works extremely well, so that may be the answer. A new diaphragm that is universally sized is coming to market, and condoms are always an option.
Are breast implants safe?
Stafford R. Broumand, MD, Associate Clinical Professor of Plastic Surgery, Icahn School of Medicine: Silicone implants are safe. But there are issues that need to be clarified. Different types of implants have different types of issues. Lately, anaplastic large cell lymphoma (ALCL) has been diagnosed in women with textured implants. We don’t really know why that is. We now use smooth implants because there is no incidence of ALCL. Women who have textured implants and those who are not sure whether they have them should discuss this with their physician.
Can a liquid biopsy detect cancer cells in the blood of someone who is not known to have breast cancer or determine if a patient’s cancer is returning? Can it also be used to track a patient’s response to treatment?
Hanna Y. Irie, MD, PhD, Associate Professor of Medicine (Hematology and Medical Oncology), and Oncological Sciences: A liquid biopsy is a blood test aimed at detecting small amounts of cancer cells circulating in the blood stream, as well as the footprint, or DNA, of these cancer cells. Most studies use the biopsy in the context of advanced cancers. However, because of the power of liquid biopsy in detecting small amounts of cancer, researchers at the Dubin Breast Center are trying to understand its utility in patients diagnosed with triple negative aggressive breast cancer. We are studying whether it can detect recurrences at an earlier stage than either CT scans or MRIs.
What is the right screening for me based on my family history?
Hank Schmidt, MD, PhD, Associate Professor of Surgery, Director, High-Risk Program at the Dubin Breast Center: The big question is ‘what is your risk?’ There are a lot of ways to risk stratify patients to find out where they lie on the spectrum of risk. Some patients have a strong family history of cancer but their genetic testing is negative. We look at a variety of risk factors. Then we define a plan for risk management. A big component of our surveillance is imaging. For women over age 40 mammography is the standard. We always begin with that. Then, based on personal risk, we decide whether to add ultrasound on a yearly basis, or for higher-risk patients or someone who wants to be more aggressive, we’ll consider adding annual breast MRI.